Central neurocytomas are relatively rare well-differentiated neoplasms that arise from neuronal cells with the atypical variant having been noted to be more uncommon/aggressive. Herein, we present a case of an atypical neurocytoma confined to the third ventricle and in so doing review surgical management and outcomes associated with such tumors. We identify a number of cases of central neurocytomas within the third ventricle and clarify both clinical presentation and disease course. Central neurocytomas within the third ventricle are rare while atypical neurocytomas confined to the third ventricle are exceedingly rare. Review of the literature suggests gross total resection should be the preferred treatment modality for these tumors, atypical or not. When only subtotal resection can be achieved, postoperative radiation might be helpful to control tumor recurrence rates.
Introduction
Central neurocytomas were first described in 1982 by Hassoun et al. and are regarded as rare and generally benign, welldifferentiated World Health Organization (WHO) grade II neoplasms of neuronal cell origin [1] . Central neurocytomas typically occur within the ventricular system with the vast majority of cases involving the lateral ventricles. Uncommon cases have been reported in which central neurocytomas arise and remain confined within the third ventricle [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Of note, central neurocytomas may also arise in the fourth ventricle as well as in extraventricular sites including the pineal region, aqueduct of Sylvius, cerebral hemispheres, thalamus, pons, cerebellum, amygdala, retina, and cervical spinal cord [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Treatment typically involves gross total resection (GTR) when possible; recurrence is rare but, in some instances, may involve dissemination to other sites along the cerebrospinal fluid (CSF) transport system (e.g., reaching as far as the cervical and thoracic spine) [22] [23] [24] [25] [26] [27] . Soylemezoglu et al. suggested the adoption of the term atypical central neurocytoma, a variant equivalent to a WHO grade III that is associated with a worse prognosis and a greater chance of recurrence, for those tumors characterized by a mitotic rate > 2% [28] . Although atypical neurocytomas arising from the third ventricle with extension into the lateral and fourth ventricles have been reported, to date there is only one case of an atypical neurocytoma solely confined to the third ventricle [11, 25, [29] [30] [31] . Herein, we present only the second case and the first detailed description of an atypical neurocytoma confined to the third ventricle without involvement of the rest of the ventricular system. In so doing, we also systematically review the central neurocytoma literature and report on outcomes associated with such neoplasms.
Methods

Literature Search
A comprehensive review of the literature was performed by searching MEDLINE PubMed using the terms "central neurocytoma," "intraventricular neurocytoma," "third ventricle neurocytoma," "atypical neurocytoma," "aggressive neurocytoma," and "recurrent neurocytoma." This search yielded an extensive library of 332 manuscripts. However, only 12 cases involving the third ventricle alone were available in the literature with only one of them being an atypical variant [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
Case Report
History and Presentation
A 57-year-old male presented with dizziness, loss of balance, and episodes of incontinence for 1 month with radiographic evidence of obstructive hydrocephalus. Neurological examination was significant for mild ataxia upon heel-to-toe walking. Magnetic resonance imaging (MRI) demonstrated a poorly enhancing mass, which was isointense on T1-weighted imaging and hyperintense on T2-weighted imaging (Fig. 1a ). It appeared intraventricular, causing proximal obstruction of the lateral and third ventricles. However, fluid-attenuated inversion recovery (FLAIR) hyperintensity was seen in the thalamus, worrisome for possible infiltration (Fig. 1b ). Based on its location and radiographic appearance, a likely preoperative differential diagnosis included infiltrating thalamic glioma, which is largely managed non-surgically. Therefore, tissue diagnosis via a minimally invasive approach was recommended in order to dictate further therapy decisions.
Operation
The patient first underwent an endoscopic biopsy via a right frontal approach at the time that an endoscopic third ventriculostomy (ETV) was performed for management of the patient's hydrocephalus. Endoscopic views of the tumor revealed a grayish mass similar in appearance to the normal surrounding tissue, which made identifying the edges of the tumor difficult. After the initial biopsy revealed a diagnosis of central neurocytoma with atypia, recommendation was made for maximal safe resection via a bifrontal craniotomy for interhemispheric, anterior transcallosal, and interforniceal approach to which the patient agreed. Resection of the tumor was challenged by significant hypervascularity that was not appreciated on preoperative imaging, with arterial feeders arising from the floor of the third ventricle and with drainage posteriorly into the deep venous structures. Tumor at the upper posterior aspect of the third ventricle was clearly adherent to and likely infiltrating the thalamic border as seen on FLAIR ( Fig. 1c ). Tumor infiltrating the thalamus was left unresected to prevent thalamic injury, resulting in a subtotal resection ( Fig. 1d ).
Postoperative Course
The patient underwent resection of his tumor without apparent intraoperative complications. Postoperatively, he returned to his neurologically intact baseline with only the exception of minimal decrease in spontaneous speech. This speech hesitancy was further evaluated with prolonged electroencephalogram (EEG) monitoring, which ruled out ongoing seizures. A temporary ventriculostomy drain that had been originally placed during the initial ETV surgery and replaced at the time of resection surgery was successfully weaned approximately 24 h postoperatively. The patient eventually returned to his preoperative baseline without the need for further interventions and was discharged home in stable condition four days post-resection. Future plans included postoperative radiation, which was discussed with the patient prior to discharge. Unfortunately, he failed to present for any of his scheduled follow-up appointments to discuss further therapy and his ultimate clinical outcome remains unknown despite several attempts to contact him and his family ( Fig. 2 ).
Tissue Pathology
Histopathological examination of resected tissue demonstrated a hypercellular neoplasm characterized by cells with round monotonous nuclei and fibrillar cytoplasm ( Fig. 3a) . A smear preparation performed intraoperatively showed few processes associated with the tumor cells, with tissue sections demonstrating a finely fibrillary background. Some endothelial proliferation was also seen ( Fig. 3b ). Some tumor cells stained for synaptophysin with weak immunopositivity for neuronal nuclei (NeuN). Ki-67 (MIB-1 labeling index) staining demonstrated a mitotic rate of up to 10%. As only rare cells stained with leukocyte common antigen (LCA), mitotic activity was due to tumor cell proliferation; diagnosis was consistent with that of atypical central neurocytoma.
Systematic Review of the Literature
Review of all cases of central neurocytoma arising in the third ventricle including our case (n = 19, Table 1 ) revealed 13 patients (68.4%) as having central neurocytoma confined to the third ventricle, 3 (15.8%) extending into the lateral ventricles, 2 (10.5%) into the fourth ventricle, and 1 (5.3%) into the hypothalamus. Including our case, 5 (26.3%) were of the atypical neurocytoma variant and only 2 (10.5%) were confined to the third ventricle. The median age was revealed to be 31.5 years (mean 32.6 years), ranging from 6 to 66 years. Of the 19 patients, 12 (63.2%) were males, 6 (31.6%) were females, and 1 was unspecified (5.3%). Presenting symptoms were those characteristic of obstructive hydrocephalus, which was confirmed by imaging in 84% of patients. Headache was present in 84.2% of patients, ataxia in 31.6%, nausea/vomiting in 15.8%, and loss of consciousness and vision changes also in 15.8%. Three patients had atypical presentations with one patient presenting with intraventricular hemorrhage, another with weakness, and one with tumor extension into the hypothalamus presenting with gigantism. Fourteen patients (73.7%) were treated surgically, and only 26.3% of these received adjuvant radiotherapy. GTR was achieved in 57.9% of patients treated surgically with the rest having subtotal resections. Surgical complications including excessive blood loss and intraoperative diabetes insipidus were listed as the reason for subtotal resection in one of the cases; the other cases did not specify a reason. Only two patients (10.5%) received radiotherapy as their main intervention (Gamma Knife radiotherapy and radiotherapy plus ventriculoperitoneal shunt, respectively). Probability of progression-free survival (PFS) as a function of time is depicted in Fig. 2 and demonstrates the benign course of this tumor. In this small series of third ventricular neurocytomas, PFS remains 100% at 3 years and 85% at 7 years.
Discussion
Central neurocytomas, first described by Hassoun et al. in 1982 , are relatively rare well-differentiated neoplasms that arise from neuronal cells [1] . These tumors are most commonly diagnosed during the second/third decades of life and are generally associated with favorable outcomes [32] . Because they most often occur within the lateral ventricles with rare invasion into the third ventricle, it was initially suggested that these tumors arose either from the septum pellucidum or the subependymal matrix layer [1, 33] . However, more recent reports of central neurocytomas originating in the fourth ventricle as well as in extraventricular sites suggest that they may arise around the walls anywhere along the ventricular system [12] [13] [14] [15] [16] [17] [18] [19] [20] . Herein, we present only the second case and the first detailed description of an atypical neurocytoma confined to the third ventricle without involvement of the rest of the ventricular system. A wide variety of tumors may arise within the third ventricle. The most common lesions in the region of the anterior third ventricle are colloid cysts and gliomas, with suprasellar tumors such as craniopharyngiomas, macroadenomas, and meningiomas occurring infrequently 
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Abbreviations: M, Male; F, female; GTR, gross total resection; STR, subtotal resection; RT, radiation therapy; VPS, ventriculoperitoneal shunt; GKRS, Gamma Knife radiosurgery [34] . Tumors of the posterior third ventricle include primary pineal tumors, gliomas, pineal teratomas, and choroid plexus papillomas [34] . Given such a robust differential diagnosis, it is prudent to consider alternatives with regard to the preoperative identification of central neurocytomas within the third ventricle. As it was the case with outpatient, instances where radiographic diagnosis is unclear and management will differ greatly depending on the pathology at hand, tissue diagnosis can be a helpful first step in guiding the treatment decisionmaking process. Histologically, neurocytomas have often been confused with ependymomas and oligodendrogliomas due to their remarkable similarities when analyzed using common stains (e.g., hematoxylin and eosin (H&E)) [35] . However, the establishment of detailed immunocytochemical characteristics common to central neurocytomas has made it possible to identify these tumors as a separate entity [4] . Current diagnostic guidelines describe central neurocytoma as staining positively for synaptophysin and Neu-N, while remaining negative for GFAP [36] ; all of which held true for our patient. Central neurocytomas also have an MIB-1 labeling index ≤ 2% with the distinction between them and the atypical variant being a MIB-1 labeling index > 2% [28] . Further histologic criteria for central neurocytoma describe the tumor as having welldeveloped neuronal characteristics, salt and pepper chromatin, no infiltrating margin, no endothelial proliferation, emptyappearing halos reminiscent of oligodendroglioma, rarely with necrosis, and having an eosinophilic fibrillar matrix in the background with rare Homer Wright rosettes and ganglion cells [37] . While our case demonstrated the characteristic fibrillar matrix seen in central neurocytomas, it also demonstrated some endothelial proliferation that is atypical for this type of tumor. Nevertheless, our case met enough criteria for atypical central neurocytoma based on histopathological and immunohistochemical analyses. The most recent update to the WHO classification of central nervous system tumors has left the criteria for diagnosis of central neurocytoma largely unchanged, with the only exception being the addition of absence of isocitrate dehydrogenase (IDH) mutations [38] . Unfortunately, testing for IDH mutations was not widely used at the time the patient was treated at our institution.
Due to the relatively recent classification of central neurocytomas, much of our understanding comes from retrospective series of previously misdiagnosed cases. For this reason, the real incidence of central neurocytoma is difficult to evaluate, although it is believed to account for approximately 0.25-0.5% of all brain tumors [33] . It is important to note that conflicting terminology, such as primary neuroblastoma [2, 7, 39] and differentiated neuroblastoma [40, 41] , have been used to describe central neurocytoma, further complicating identification of case reports referring to this entity.
Typically, these tumors exhibit slow progression and are classified as low-grade tumors corresponding to WHO grade II [42] . However, accounts of more aggressive forms of central neurocytoma associated with recurrence and a worse prognosis have also been reported and are referred to as atypical neurocytomas (i.e., WHO grade III) [25, 27, 28, 30, 43, 44] . These aggressive forms of central neurocytoma, characterized by having a mitotic rate > 2%, are associated with significantly shorter patient survival times and greater rates of recurrence [28] .
Various factors have been shown to influence the outcomes of patients diagnosed with central neurocytomas. Tumor volume ≥ 30 cm 3 , subtotal resection, and a mitotic count ≥ 3 per 10 high-power fields are significant predictors of recurrence for central neurocytomas [45] . In a study involving 45 patients comparing typical and atypical central neurocytomas, Leenstra et al. found a 90 vs. 63% 10-year survival rate and a 74 vs. 46% (p = 0.41) local control rate, respectively. This data support the notion that atypical neurocytomas have poorer prognosis than typical neurocytomas; however, it is estimated that less than 20% of all central neurocytomas display atypical features making them exceedingly rare [46] . It has also been described that at 150 months follow-up, patients with MIB-1 labeling index > 2% had a relapse rate of 63 versus 22% for those with an MIB-1 labeling index ≤ 2% [47] [48] [49] .
Currently, the first-line treatment modality for neurocytomas is surgical resection, with the goal being GTR. Surgical resection of tumors of the third ventricle is highly challenging due to the complex anatomy. A variety of surgical approaches may be used to resect third ventricular tumors. These include approaches through the foramen of Monro and third ventricular roof via the transcortical or interhemispheric transcallosal approach, through the lamina terminalis via the subfrontal approach, through the pineal region via the infratentorial supracerebellar approach, and through the crus of the fornix from the posterior aspect of the lateral ventricle [50] . The choice of approach is dependent on the surgeon's comfort and location of the tumor within the third ventricle. In our case, an interhemispheric transcallosal approach was chosen due to surgeon's comfort with this approach, midline location of the tumor, and to improve visualization given concerns for thalamic involvement.
Adjuvant radiation therapy has also been reported in cases where GTR has not been possible, but its efficacy has remained somewhat controversial. A study involving 85 patients by Rades et al. compared outcomes when having complete resection alone, complete resection with radiation, incomplete resection alone, and incomplete resection with radiation. Local control rates and survival rates at 5 years were found to be 57% and 93% after complete resection, 53% and 90% after complete resection plus radiation, 7% and 43% after partial resection, and 70% and 78% after partial resection plus radiation, respectively [51] . As evidenced from the data, patients who underwent total resection had better survival rates and local control rates than those who only underwent partial resection. Furthermore, those who underwent partial resection benefited greatly from radiation in comparison with patients who had incomplete resection and no radiation. Radiation therapy, however, demonstrated no significant benefits for patients in which total resection was possible. Another retrospective study by Rades et al. defined 54 Gy as the optimal radiation dose for patients with subtotal resection, demonstrating a 98% 10-year survival rate and local control rates of 98% and 89% at 5-and 10-year follow-up, respectively [51] .
Although recurrence is rare following complete resection, it may still occur, particularly in patients having tumors with high mitotic rates [22] [23] [24] [25] [26] . Therefore, alternative treatments such as Gamma Knife radiosurgery [52] [53] [54] [55] , linear accelerator radiosurgery [56] , stereotactic radiosurgery [57, 58] , and polychemotherapy (4 cycles of carboplatin 500 mg/m 2 , etoposide 100 mg/m 2 , and ifosfamide, 3 g/m 2 ) [59] have been suggested for such cases where GTR was not possible or when recurrence is observed. While promising, these alternative treatments require further evaluation due to the limited number of studied cases.
In conclusion, central neurocytomas are rare, slow progressing tumors that are generally associated with favorable outcomes. However, there exists an even more aggressive and exceedingly more rare variant known as atypical central neurocytoma. This variant is associated with higher recurrence and worse survival rates. Given their rarity, level 1 evidence to support different treatment modalities over others is lacking. Nevertheless, based on the existing body of literature, surgical resection with a goal toward gross total resection when feasible should be the first-line of treatment. In those cases where challenging anatomy prevents gross total resection, radiation therapy appears to be the most beneficial treatment adjunct in improving local control and 5-year survival rates. Further studies are needed to determine superiority among different radiation dosing and delivery modalities over others.
Limitations
Although we have performed an extensive review of the literature, we may have missed cases published in the literature as headings of manuscripts on third ventricular neurocytomas may not include the search terms utilized; the literature included in our review covers publications from 1988 to 2019. Further, as the WHO classification for tumors of the central nervous system has changed over time, some of the cases included in our literature analysis may represent patients with tumors no longer classified as neurocytoma by the updated WHO classification. Finally, it is impossible to determine with absolute certainty that our own case does not similarly suffer from these limitations. Only recently was a lack of IDH mutations included as part of the criteria for diagnosis of central neurocytoma, and as a result testing was not performed at the time our patient was treated. Similarly, we are unable to report this patient's H3K27M mutation status, which is a now widely accepted criterion for diagnosis of infiltrative midline gliomas.
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